

Appl. No. 09/485, 03
Amdt. dated August 8, 2003
Reply to Office action of April 9, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (canceled)

Claim 8 (currently amended): A method for treating a bone resorption-associated disease comprising administering to a subject in need thereof an effective amount of a selective iNOS inhibitor as a bone mass-maintenance drug to maintain bone mass.

Claim 9 (previously presented): The method as claimed in claim 8, wherein the bone resorption-associated disease is osteoporosis.


Claims 10-11 (canceled)

Claim 12 (withdrawn): The method as claim in claim 8, wherein the selective iNOS inhibitor is used as a an inhibitor of bone metastasis of tumor cells.

Claim 13 (withdrawn): The method as claimed in claim 8, wherein the bone resorption-associated disease is nephritis.

Appl. No. 09/485,333
Amdt. dated August 8, 2003
Reply to Office action of April 9, 2003

Claim 14 (withdrawn): The method as claimed in claim 8, wherein the selective iNOS inhibitor is used as a progression retardant of chronic renal failure.

 Claim 15 (currently amended): A kit for treating a bone resorption-associated disease comprising an effective amount of a selective iNOS inhibitor as a bone mass-maintenance drug to maintain bone mass in a pharmaceutically acceptable carrier, and instructions for treating a bone resorption-associated disease.

Claim 16 (previously presented) The kit as claimed in claim 15, wherein the bone resorption-associated disease is osteoporosis.

Claims 17-18 (canceled)

Claim 19 (withdrawn) The kit as claimed in claim 15, wherein the selective iNOS inhibitor is used as an inhibitor of bone metastasis of tumor cells.

Claim 20 (withdrawn): The kit as claimed in claim 15, wherein the bone-resorption-associated disease is nephritis.

Appl. No. 09/485 3
Amdt. dated August 8, 2003
Reply to Office action of April 9, 2003

Claim 21 (withdrawn): The kit as claimed in claim 15, wherein the selective iNOS inhibitor is used as a progression retardant of chronic renal failure.

Claim 22 (previously presented): The method according to claim 8 wherein the selective iNOS inhibitor is an inhibitor which satisfies at least one requirement selected from the group consisting of (a), (b), and (c):

a. the ratio of the IC50 level on eNOS to that on iNOS is 25 or above;

b. the ratio of the IC50 level on nNOS to that on iNOS is 15 or above; and

c. the ratio of the IC50 level on cNOS to that on iNOS is 15 or above.

Claim 23 (previously presented): The method according to claim 9 wherein the selective iNOS inhibitor is an inhibitor which satisfies at least one requirement selected from the group consisting of (a), (b), and (c):

d. the ratio of the IC50 level on eNOS to that on iNOS is 25 or above;

e. the ratio of the IC50 level on nNOS to that on iNOS is 15 or above; and

f. the ratio of the IC50 level on cNOS to that on iNOS is 15 or above.

Claim 24 (previously presented): The kit


Appl. No. 09/485 3
Amdt. dated August 8, 2003
Reply to Office action of April 9, 2003

according to claim 15 wherein the selective iNOS inhibitor is an inhibitor which satisfies at least one requirement selected from the group consisting of (a), (b) and (c):

g. the ratio of the IC50 level on eNOS to that on iNOS is 25 or above;

h. the ratio of the IC50 level on nNOS to that on iNOS is 15 or above; and

c. the ratio of the IC50 level on cNOS to that on iNOS is 15 or above.



Claim 25 (previously presented): The kit according to claim 16 wherein the selective iNOS inhibitor is an inhibitor which satisfies at least one requirement selected from the group consisting of (a), (b) and (c):

i. the ratio of the IC50 level on eNOS to that on iNOS is 25 or above;

j. the ratio of the IC50 level on nNOS to that on iNOS is 15 or above; and

c. the ratio of the IC50 level on cNOS to that on iNOS is 15 or above.

Claim 26 (new): A kit according to claim 15 wherein the composition is to be administered orally, by injection, or topically.

Appl. No. 09/485, 3
Amdt. dated August 8, 2003
Reply to Office action of April 9, 2003